There are two strategies for targeting glutamine metabolism in cancer cells: inhibition of glutaminase that can convert glutamine into glutamate and blockage of the major glutamine transporter alanine-serine-cysteine transporter 2 (ASCT2) to suppress the influx of glutamine into the cancer cells (64, 65). The gene discussed is SLC1A5; the disease is cancer.